by Takeshi Nishijima, Hirokazu Komatsu, Hiroyuki Gatanaga, Takahiro Aoki, Koji Watanabe, Ei Kinai, Haruhito Honda, Junko Tanuma, Hirohisa Yazaki, Kunihisa Tsukada, Miwako Honda, Katsuji Teruya, Yoshimi Kikuchi, Shinichi Oka
Treatment with tenofovir is sometimes associated with renal dysfunction. Limited information is available on this side effect in patients with small body weight, although the use of tenofovir will spread rapidly in Asia and Africa, where patients are likely to be of smaller body weight. Methods
In a single-center cohort, Japanese patients with HIV infection who started tenofovir-containing antiretroviral therapy were retrospectively analyzed. The incidence of tenofovir-associated renal dysfunction, defined as more than 25% decrement of estimated glomerular filtration rate (eGFR) from the baseline, was determined. The effects of small body weight and body mass index (BMI) on tenofovir-associated renal dysfunction, respectively, were estimated in univariate and multivariate Cox hazards models as the primary exposure. Other possible risk factors were evaluated by univariate analysis and those found significant were entered into the multivariate analysis. Results
The median weight of 495 patients was 63 kg. Tenofovir-related renal dysfunction occurred in 97 (19.6%) patients (incidence: 10.5 per 100 person-years). Univariate analysis showed that the incidence of tenofovir-related renal dysfunction was significantly associated with smaller body weight and BMI, respectively (per 5 kg decrement, HR?=?1.23; 95% CI, 1.10–1.37; p<0.001)(per 1 kg/m2 decrement, HR?=?1.14; 95% CI, 1.05–1.23; p?=?0.001). Old age, high baseline eGFR, low serum creatinine, low CD4 count, high HIV viral load, concurrent nephrotoxic drugs, hepatitis C infection, and current smoking were also associated with tenofovir-related renal dysfunction. Multivariate analysis identified small body weight as a significant risk (adjusted HR?=?1.13; 95% CI, 1.01–1.27; p?=?0.039), while small BMI had marginal significance (adjusted HR?=?1.07; 95% CI 1.00–1.16; p?=?0.058). Conclusion
The incidence of tenofovir-associated renal dysfunction in Japanese patients was high. Small body weight was identified as an independent risk factor for tenofovir-associated renal dysfunction. Close monitoring of renal function is advocated for patients with small body weight treated with tenofovir.